ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD38 Antibody-drug Conjugate ABBV-438

In AbbVie’s pipeline, CD38. Its studies are mostly in Multiple Myeloma, led by AbbVie.

Furthest: phase 1, since Feb 9, 20261 company-led study, 1 open or runningNext primary completion: Nov 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Feb 9, 2026Feb 9, 2026Nov 2031phase 1 · NCT07409246
  • Named in AbbVie’s own pipeline as ABBV-438, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2026First study: phase 1 study in Multiple MyelomaFirst studyNCT07409246 · 127 planned · United States, China, Israel and more

Ahead

  1. Nov 2031Primary completion: phase 1 study in Multiple MyelomaNCT07409246

TargetBeta

“CD38”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed a monoclonal antibody directed against the human cell surface glycoprotein and tumor-associated antigen (TAA) CD38 ”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 24
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07409246Multiple Myeloma · United States, China, Israel and more1RecruitingNov 2031127

How it is read

Names in the registry

  • “ABBV-438”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.